US Patent

US8592434 — Mucoadhesive buccal tablets for the treatment of orofacial herpes

Method of Use · Assigned to Bioalliance Pharma SA · Expires 2030-06-16 · 4y remaining

Vulnerability score 73/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of using prolonged release mucoadhesive buccal tablets to treat or prevent orofacial herpes.

USPTO Abstract

The present invention relates to the treatment or prevention of mucocutaneous herpes simplex virus diseases using prolonged release mucoadhesive buccal tablets comprising an acyclic guanosine antiviral agent. These tablets are particularly suitable for the treatment or prevention of orofacial herpes.

Drugs covered by this patent

Zovirax (ACYCLOVIR) · Ligand Pharms

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1460`	—	Zovirax

Patent Metadata

Patent number: US8592434
Jurisdiction: US
Classification: Method of Use
Expires: 2030-06-16
Drug substance claim: No
Drug product claim: Yes
Assignee: Bioalliance Pharma SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.